The General Breathing Record Study

Asthma Clinical Trial

— GBRS  

Official title:

An Observational Proof-of-concept Study to Explore the Waveform Characteristics of Tidal Breathing Carbon Dioxide (CO2), Measured Using the N-Tidal C™ Device, in Different Breathing Conditions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03356288
• Other study ID #: G002-17_GBRS
• Status: Completed
• Start date: August 9, 2017
• Est. completion date: July 4, 2018

Study information

• Verified date: September 2018
• Source: Cambridge Respiratory Innovations Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will test the use of a new handheld device (called the N-Tidal C), that measures a person's tidal breath carbon dioxide, in diagnosing the cause of someone's breathlessness. It will also evaluate whether this device can detect when a person's breathing problem is getting worse.

Description:

When a person breathes out, they exhale carbon dioxide (CO2). The CO2 levels in breath change as they breathe out and this makes a specific pattern, or "waveform". This waveform can tell a clinician a lot about the underlying health of a person. There are disease specific CO2 waveforms for common breathing conditions such as Asthma and Chronic Obstructive Pulmonary Disease (COPD). However up until this point there has been no accurate and non-invasive method of measuring the tidal breath CO2 waveform.

This study will test the N-Tidal C, a new handheld device that accurately measures this waveform, and whether it can differentiate different causes of breathlessness; namely asthma, heart failure, pneumonia, breathing pattern disorders and motor neurone disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: July 4, 2018
• Est. primary completion date: July 4, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

Asthma Cohort:

• A confirmed clinical diagnosis of asthma for = 6months

• Moderate to severe asthma defined as British Thoracic Society stages 3-5

• 2 or more exacerbations in the previous 12 months with at least 1 exacerbation within the last 6 months.

• Exacerbation free for 2 weeks (defined as no increased dose or course of oral corticosteroids or antibiotics).

Breathing Pattern Disorder Cohort

• A Clinical diagnosis of a Breathing Pattern Disorder (BPD)

Chronic heart failure Cohort:

• A confirmed clinical diagnosis of chronic heart failure with both of the following:

1. A Left Ventricular Ejection Fraction <40% on most recent imaging within the last 12 months.

2. New York Heart Association Class 2-4

• Admitted with an acute decompensation of their heart failure to hospital within the last 6 months

Motor Neurone Disease Cohort:

• A confirmed clinical diagnosis of Motor Neurone Disease

• Forced Vital Capacity (FVC) of less than 60% of predicted, sleep disordered breathing or daytime hypercapnia.

• Established on Home Non-Invasive Ventilation.

Pneumonia Cohort:

• A confirmed clinical diagnosis of Pneumonia supported by evidence of consolidation on a chest X-ray (CXR) or computed tomography (CT) imaging.

Healthy Cohort:

• No known history of lung, cardiac or neuromuscular disease (defined as no current clinical diagnosis of, or be receiving treatment for, a lung, cardiac or neuromuscular disease). A Body Mass Index of less than 40. A Non-smoker, or an ex-smoker with less than a 5 pack year history.

Exclusion Criteria:

• Known other lung, chest wall, neuromuscular, cardiac or other comorbidity or abnormality that would affect spirometry and/or other measures of lung function or Tidal Breath Carbon Dioxide measurements.

• In the opinion of the clinical investigator, the participant would have difficulty completing the study procedures consistently over the course of 6 months.

Related Conditions & MeSH terms

• Asthma
• Breathlessness
• Dyspnea
• Heart Failure
• Motor Neuron Disease
• Pneumonia
• Vocal Cord Dysfunction

Locations

Country	Name	City	State
United Kingdom	Portsmouth Hospitals NHS Trust	Portsmouth	Hampshire

Sponsors (2)

Lead Sponsor	Collaborator
Cambridge Respiratory Innovations Limited	Innovate UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The tidal breathing carbon dioxide waveform for each of the breathing conditions as measured by the N-Tidal C device		12 months
Secondary	Change in the Tidal Breathing carbon dioxide waveform over time	Change in the tidal breathing carbon dioxide waveform, in each disease, over the 6 months.	Change measures - baseline to 6 months
Secondary	Disease Control in asthma patients	The Asthma Control Questionnaire Score for the Asthma patients	12 months
Secondary	Disease Improvement in Breathing Pattern Disorder patients	The Nijmegen Questionnaire Score	12 months
Secondary	Disease severity in the pneumonia patients	The CURB-65 Score	2 days
Secondary	Disease severity in heart failure patients	The Trans Thoracic Echocardiogram (TTE) result	12 months
Secondary	Hypercapnia in the motor neurone disease patients	The level of partial pressure carbon dioxide (pCO2)	12 months
Secondary	Usability of the N-Tidal C device	Measured by how frequently the patients remember to use the N-Tidal C device over 6 months	Change measures - baseline to 6 months
Secondary	Acceptability of the N-Tidal C device	Measured by a questionnaire of the participants experience of the device at the end of the study	12 months